Radiofrequency ablation of uterine leiomyomata: a new minimally invasive hysterectomy alternative

Lee, Bruce B.

doi:10.1016/s0029-7844(02)01682-4

Cited by 11 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The novel use of radiofrequency ablation under laparoscopic and intra-abdominal ultrasound guidance to treat patients with symptomatic myomas was first introduced in 2002 169. This has prompted the development of the study device (Acessa™) which carries out laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of uterine myomas in symptomatic women 170.…”

Section: Managementmentioning

confidence: 99%

Uterine fibroids: current perspectives

Khan¹,

Shehmar²,

Gupta³

2014

IJWH

307

252

View full text Add to dashboard Cite

Uterine fibroids are a major cause of morbidity in women of a reproductive age (and sometimes even after menopause). There are several factors that are attributed to underlie the development and incidence of these common tumors, but this further corroborates their relatively unknown etiology. The most likely presentation of fibroids is by their effect on the woman’s menstrual cycle or pelvic pressure symptoms. Leiomyosarcoma is a very rare entity that should be suspected in postmenopausal women with fibroid growth (and no concurrent hormone replacement therapy). The gold standard diagnostic modality for uterine fibroids appears to be gray-scale ultrasonography, with magnetic resonance imaging being a close second option in complex clinical circumstances. The management of uterine fibroids can be approached medically, surgically, and even by minimal access techniques. The recent introduction of selective progesterone receptor modulators (SPRMs) and aromatase inhibitors has added more armamentarium to the medical options of treatment. Uterine artery embolization (UAE) has now been well-recognized as a uterine-sparing (fertility-preserving) method of treating fibroids. More recently, the introduction of ultrasound waves (MRgFUS) or radiofrequency (VizAblate™ and Acessa™) for uterine fibroid ablation has added to the options of minimal access treatment. More definite surgery in the form of myomectomy or hysterectomy can be performed via the minimal access or open route methods. Our article seeks to review the already established information on uterine fibroids with added emphasis on contemporary knowledge.

show abstract

Section: Managementmentioning

confidence: 99%

Uterine fibroids: current perspectives

Khan¹,

Shehmar²,

Gupta³

2014

IJWH

307

252

View full text Add to dashboard Cite

show abstract

“…The first reported application of RFA to treat uterine fibroids was by Lee [26] in 2002. This initial report described treatment from 1999 to 2001 of 52 patients with 197 myomas ranging in size from 1 to 11 cm.…”

Section: Development Of Rfa Of Fibroidsmentioning

confidence: 99%

Radiofrequency Ablation of Uterine Fibroids: a Review

Lee

2016

Curr Obstet Gynecol Rep

View full text Add to dashboard Cite

Laparoscopic, ultrasound-guided radiofrequency ablation (RFA) is a new, FDA-cleared uterine sparing, outpatient procedure for uterine fibroids. The procedure utilizes recent technological advancements in instrumentation and imaging, allowing surgeons to treat numerous fibroids of varying size and location in a minimally invasive fashion. Early and mid-term data from multi-center clinical trials have demonstrated safety and efficacy, with resolution or improvement of symptoms and significant volume reduction. Re-intervention rates for fibroid symptoms have been low. The procedure is well tolerated with a typically uneventful and rapid recovery requiring NSAIDs only for postoperative pain. While post RFA pregnancy data are limited, the results are promising.

show abstract

“…Radiofrequency ablation (RFA) has been used to treat a variety of neoplasms, including hepatocellular carcinoma, renal cell carcinoma, hyper‐functioning parathyroid adenoma, and prostatic hyperplasia, as well as hepatic, cerebral, and retroperitoneal metastases from other primary tumors [1]. Yet, there are few reports using RFA in the treatment of gynecologic disease [2]. In this study, pathologic features and the expression of estrogen receptor (ER) and progesterone receptor (PR) were observed following RFA treatment in human uterine leiomyomas to explore the mechanism by which RFA works, and provide guidance for clinical treatment.…”

Section: Introductionmentioning

confidence: 99%